Moclobemide and selegeline in the treatment of depression in Parkinson's disease

October 1997
Journal of Neurology, Neurosurgery & Psychiatry;Oct1997, Vol. 63 Issue 4, p547
Academic Journal
No abstract available.


Related Articles

  • New capsule form of Eldepryl replaces tablet for Parkinson's disease.  // Modern Medicine;Jul96, Vol. 64 Issue 7, p39 

    Reports that selegeline, a medication for Parkinson's disease has a new capsule form which replaces its tablet form.

  • BEATING Parkinson's. Campbell, Annette; Gibson, Donna // Woman's Day (Australia Edition);4/18/2005, Vol. 57 Issue 16, p78 

    Provides information on Parkinson's disease. Cause of the disease; Manifestations of the disease; Available treatments; Relation of depression with Parkinsonism.

  • Moclobemide.  // Reactions Weekly;10/22/2005, Issue 1074, p9 

    Highlights a case report about a man who developed pseudohallucinations during treatment with moclobemide for severe depression. Symptoms that were experienced by the man; Range of the moclobemide plasma concentration of the patient; Provision of mirtazapine to the man.

  • Monoamine Oxidase Inhibitors: A Perspective on their Use in the Elderly. Volz, H-P.; Gleiter, C.H. // Drugs & Aging;1998, Vol. 13 Issue 5, p341 

    Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk...

  • Depression in Parkinson's disease: diagnosis and management. Latoo, Javed; Mistry, Minal; Dunne, Francis J. // British Journal of Hospital Medicine (17508460);Jun2012, Vol. 73 Issue 6, p331 

    Parkinson's disease has a high prevalence of psychiatric comorbidity including depression. This review highlights the epidemiology, aetiology and diagnosis of depression in patients with Parkinson's disease. Recommendations are made on treatment and a closer partnership between neurology and...

  • Personal View.  // British Medical Journal (Clinical Research Edition);8/27/1983, Vol. 287 Issue 6392, p607 

    Relates the struggle of the author with Parkinson's disease in Great Britain. Feeling of depression; Treatment with levodopa and Sinemet Plus; Identification of affected parts.

  • Depression: A Primary Symptom of Parkinson Disease? Silverman, Franklin H.; Henry, Barbara // Journal of Rehabilitation;Jul-Sep89, Vol. 55 Issue 3 

    Examines the correlation of occurrence of depression with Parkinson disease. Identification of depression as primary cause of the disease; Treatment of fifty-two persons with disease; Administration of semantic differential task.

  • Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Amrein, Roman; Stabl, Max; Henauer, Stephan; Affolter, Eva; Jonkanski, Iris; Amrein, R; Stabl, M; Henauer, S; Affolter, E; Jonkanski, I // Canadian Journal of Psychiatry;Dec1997, Vol. 42 Issue 10, p1043 

    Objective: To review the efficacy and safety of moclobemide in comparison with TCAs (for our purposes, "TCAs" will represent tricyclic and tetracyclic antidepressants, including maprotilin and mianserin) and selective serotonin reuptake inhibitors (SSRIs) in elderly depressed...

  • European Union funds research into Parkinson's.  // Nursing Standard;4/21/2004, Vol. 18 Issue 32, p6 

    Reports that Ceri Rayner, a Parkinson's specialist nurse, is playing a leading part in European research into new treatment programs for people with the disease. Rayner to present a 10-week series of workshops on psychological problems such as depression and anxiety associated with Parkinson's.

  • Clinical Applications of MAO-Inhibitors. Riederer, P.; Lachenmayer, L.; Laux, G. // Current Medicinal Chemistry;Aug2004, Vol. 11 Issue 15, p2033 

    Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given on the use of irreversible MAO-I's as well as on reversible ones. Benefit and side effects...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics